The central target of $27 reflects the mean of six current, individually attributed analyst targets rather than a single firm's view: Roth MKM at about $10.50 (Neutral), B. Riley Securities at $21 (Buy), Piper Sandler at $25 (Buy), Jones at $25 (Buy), Cantor Fitzgerald at $28 (Buy), and Oppenheimer at $54 (Outperform). The mean works out to approximately $27.25, rounded to $27 for readability. The low-to-high spread of roughly $10.50 to $54 is exceptionally wide and mirrors deep disagreement over deramiocel's approval odds. Bullish analysts cite HOPE-3 data and first-in-class positioning; more cautious analysts point to the prior CRL and regulatory uncertainty. Notably, Roth MKM assigns only about 25% odds to approval at the upcoming decision date and 75% odds to a delay or another CRL — a stark contrast with targets in the $50s. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
With a recent close near $8.30, CAPR trades toward the lower end of its 52-week range of roughly $2.96 to $40.37. Reaching $27 implies about 225% upside, categorizing the required move as very large. In practice, any path toward $27 runs through the FDA: approval would likely reprice the shares sharply higher, while a second CRL or another delay would likely pressure them. The stock's December 2025 surge above $40 after positive HOPE-3 results shows how quickly sentiment can shift, but the subsequent retreat into single digits underscores how fragile pre-approval valuations can be.
The core bull case rests on deramiocel becoming the first FDA-approved treatment for DMD cardiomyopathy, a high-unmet-need indication. The Phase 3 HOPE-3 trial met its primary goal, and the company has resubmitted its Biologics License Application (BLA) with an expanded efficacy package. A priority review and the absence of additional clinical-study requirements could support a more constructive valuation. A $150 million public offering completed in December 2025 also strengthened the balance sheet, funding manufacturing and commercialization preparations.
The principal obstacle is regulatory risk. The FDA previously issued a CRL, and Roth MKM views approval at the current decision date as unlikely. The company remains unprofitable — it reported a GAAP net loss of about $40.7 million in the quarter ended June 30, 2026 — and further capital raises could dilute existing holders. High short interest (roughly 35% of float in recent reports) adds volatility, and biotech sector-wide risk appetite can compress valuations quickly. A delay or rejection would undermine the higher end of the target range.
The shares sit near the bottom of a 52-week range of about $2.96 to $40.37, with the prior spike above $40 acting as a distant overhead reference point. A durable resistance zone is difficult to establish given the volatility, but the $10 area is a nearby psychological level, and a sustained move above it could signal renewed momentum. Support is less well-defined near current levels, with the year's low around $2.96 serving as an extreme downside marker.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual assumptions vary. The decisive near-term event is the FDA decision on deramiocel around the November 22, 2026 PDUFA (Prescription Drug User Fee Act) date. Investors should also watch subsequent analyst rating and target revisions, quarterly cash burn and financing activity, any communication from the FDA about additional data requirements, and broader biotech sentiment. Each of these can meaningfully reshape the probability-weighted outlook behind the $27 mean. From what I see, the binary nature of the catalyst makes ongoing monitoring essential.
I frequently rely on Tickeron’s AI Daily Buy/Sell Signals to help track high-volatility biotech names where sentiment can flip quickly. These AI-driven signals monitor technical behavior and market conditions across thousands of stocks, offering a practical way to surface potential opportunities and adjust positions without relying solely on manual review. It has become a useful part of my routine for names facing binary events like the upcoming FDA decision.
The question of whether CAPR can reach $27 is ultimately a question about deramiocel's regulatory fate. The $27 central target — the mean of six current analyst targets ranging from about $10.50 to $54 — sits roughly 225% above the recent price, and only approval-oriented outcomes plausibly justify the higher half of that range. The strongest support is the clinical data and an underserved indication; the greatest obstacles are the prior CRL, continued losses, dilution risk, and the binary nature of the upcoming FDA decision. With such a wide spread of analyst views, the target is best read as a weighted view of a highly uncertain outcome rather than a forecast. Investors should monitor the FDA decision, subsequent analyst revisions, and financing developments.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CAPR moved above its 50-day moving average on November 03, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 36 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on CAPR as a result. In 70 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for CAPR just turned positive on October 29, 2026. Looking at past instances where CAPR's MACD turned positive, the stock continued to rise in 33 of 42 cases over the following month. The odds of a continued upward trend are 79%.
The 10-day moving average for CAPR crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.
Following a +14.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAPR advanced for three days, in 232 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The 10-day RSI Indicator for CAPR moved out of overbought territory on November 12, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 26 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 48 of 56 cases where CAPR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAPR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
CAPR broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CAPR entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. CAPR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.125) is normal, around the industry mean (3.592). P/E Ratio (-3.673) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (7.610) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (125.000) is also within normal values, averaging (442.120).
The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CAPR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Develops innovative products for the treatment of cardiovascular diseases
Industry Biotechnology